|
1
|
Padala SA and Barsouk A, Thandra KC,
Saginala K, Mohammed A, Vakiti A, Rawla P and Barsouk A:
Epidemiology of renal cell carcinoma. World J Oncol. 11:79–87.
2020. View Article : Google Scholar
|
|
2
|
Shen H, Luo G and Chen Q: Long noncoding
RNAs as tumorigenic factors and therapeutic targets for renal cell
carcinoma. Cancer Cell Int. 21:1102021. View Article : Google Scholar
|
|
3
|
Sun M, Thuret R, Abdollah F, Lughezzani G,
Schmitges J, Tian Z, Shariat SF, Montorsi F, Patard JJ, Perrotte P
and Karakiewicz PI: Age-adjusted incidence, mortality, and survival
rates of stage-specific renal cell carcinoma in North America: A
trend analysis. Eur Urol. 59:135–141. 2011. View Article : Google Scholar
|
|
4
|
Weyerer V, Strissel PL, Stohr C, Eckstein
M, Wach S, Taubert H, Brandl L, Geppert CI, Wullich B, Cynis H, et
al: Endogenous Retroviral-K envelope is a novel tumor antigen and
prognostic indicator of renal cell carcinoma. Front Oncol.
11:6571872021. View Article : Google Scholar
|
|
5
|
Tacconi EMC, Tuthill M and Protheroe A:
Review of adjuvant therapies in renal cell carcinoma: Evidence to
date. Onco Targets Ther. 13:12301–12316. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maher ER: Hereditary renal cell carcinoma
syndromes: Diagnosis, surveillance and management. World J Urol.
36:1891–1898. 2018. View Article : Google Scholar
|
|
8
|
Gallan AJ, Parilla M, Segal J, Ritterhouse
L and Antic T: BAP1-Mutated clear cell renal cell carcinoma. Am J
Clin Pathol. 155:718–728. 2021. View Article : Google Scholar
|
|
9
|
Kim BJ, Kim JH, Kim HS and Zang DY:
Prognostic and predictive value of VHL gene alteration in renal
cell carcinoma: A meta-analysis and review. Oncotarget.
8:13979–13985. 2017. View Article : Google Scholar
|
|
10
|
Ciomborowska-Basheer J, Staszak K, Kubiak
MR and Makalowska I: Not so dead genes-retrocopies as regulators of
their disease-related progenitors and hosts. Cells. 10:9122021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Q, Tian Y, Hu G, Liang Y, Bai W and Li
H: Highly expressed antisense noncoding RNA in the INK4 locus
promotes growth and invasion of renal clear carcinoma cells via the
β-catenin pathway. Oncol Res. 25:1373–1382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang G, Li H and Hou Y: LncRNA MAGI2-AS3
inhibits tumor progression and angiogenesis by regulating ACY1 via
interacting with transcription factor HEY1 in clear cell renal cell
carcinoma. Cancer Gene Ther. 29:585–596. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheng T, Shuang W, Ye D, Zhang W, Yang Z,
Fang W, Xu H, Gu M, Xu W and Guan C: SNHG16 promotes cell
proliferation and inhibits cell apoptosis via regulation of the
miR-1303-p/STARD9 axis in clear cell renal cell carcinoma. Cell
Signal. 84:1100132021. View Article : Google Scholar
|
|
14
|
Zhang J, Jin S, Xiao W, Zhu X, Jia C and
Lin Z: Long noncoding RNA LINC00641 promotes renal cell carcinoma
progression via sponging microRNA-340-5p. Cancer Cell Int.
21:2102021. View Article : Google Scholar
|
|
15
|
Zhang F, Wang XS, Tang B, Li PA, Wen Y and
Yu PW: Long non-coding RNA FTX promotes gastric cancer progression
by targeting miR-215. Eur Rev Med Pharmacol Sci. 24:3037–3048.
2020.
|
|
16
|
Huo X and Wang H, Huo B, Wang L, Yang K,
Wang J, Wang L and Wang H: FTX contributes to cell proliferation
and migration in lung adenocarcinoma via targeting miR-335-5p/NUCB2
axis. Cancer Cell Int. 20:892020. View Article : Google Scholar
|
|
17
|
He X, Sun F, Guo F, Wang K, Gao Y, Feng Y,
Song B, Li W and Li Y: Knockdown of long noncoding RNA FTX inhibits
proliferation, migration, and invasion in renal cell carcinoma
cells. Oncol Res. 25:157–166. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hao Z, Zhang H and Cowell J:
Ubiquitin-conjugating enzyme UBE2C: Molecular biology, role in
tumorigenesis, and potential as a biomarker. Tumour Biol.
33:723–730. 2012. View Article : Google Scholar
|
|
19
|
Xie C, Powell C, Yao M, Wu J and Dong Q:
Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. Int
J Biochem Cell Biol. 47:113–117. 2014. View Article : Google Scholar
|
|
20
|
Chen Z and Wang L: The clinical
significance of <em>UBE2C</em> gene in progression of
renal cell carcinoma. Eur J Histochem. 65:31962021. View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Capitanio U, Bensalah K, Bex A, Boorjian
SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P:
Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019.
View Article : Google Scholar
|
|
23
|
Larroquette M, Peyraud F, Domblides C,
Lefort F, Bernhard JC, Ravaud A and Gross-Goupil M: Adjuvant
therapy in renal cell carcinoma: Current knowledges and future
perspectives. Cancer Treat Rev. 97:1022072021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Escudier B, Pluzanska A, Koralewski P,
Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar
B, Bajetta E, et al: Bevacizumab plus interferon alfa-2a for
treatment of metastatic renal cell carcinoma: A randomised,
double-blind phase III trial. Lancet. 370:2103–2111. 2007.
View Article : Google Scholar
|
|
26
|
Yang S, de Souza P, Alemao E and Purvis J:
Quality of life in patients with advanced renal cell carcinoma
treated with temsirolimus or interferon-alpha. Br J Cancer.
102:1456–1460. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Motzer RJ, Escudier B, McDermott DF, Arén
Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthélémy
P, Hammers HJ, et al: Survival outcomes and independent response
assessment with nivolumab plus ipilimumab versus sunitinib in
patients with advanced renal cell carcinoma: 42-month follow-up of
a randomized phase 3 clinical trial. J Immunother Cancer.
8:e0008912020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen H, Liu T, Ouyang H, Lin S, Zhong H,
Zhang H and Yang Y: Upregulation of FTX promotes osteosarcoma
tumorigenesis by increasing SOX4 expression via miR-214-5p. Onco
Targets Ther. 13:7125–7136. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao K, Ye Z, Li Y, Li C, Yang X, Chen Q
and Xing C: LncRNA FTX contributes to the progression of colorectal
cancer through regulating miR-192-5p/EIF5A2 axis. Onco Targets
Ther. 13:2677–2688. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jin S, He J, Zhou Y, Wu D, Li J and Gao W:
LncRNA FTX activates FOXA2 expression to inhibit non-small-cell
lung cancer proliferation and metastasis. J Cell Mol Med.
24:4839–4849. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin Y, Sheng Y, Chen J, Hu C, Zhou Z and
Yuan C: The function of LncRNA FTX in several common cancers. Curr
Pharm Des. 27:2381–2386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsiakanikas P, Giaginis C, Kontos CK and
Scorilas A: Clinical utility of microRNAs in renal cell carcinoma:
Current evidence and future perspectives. Expert Rev Mol Diagn.
18:981–991. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang J, Xie S, Liu J, Li T, Wang W and Xie
Z: MicroRNA-4429 suppresses proliferation of prostate cancer cells
by targeting distal-less homeobox 1 and inactivating the
Wnt/β-catenin pathway. BMC Urol. 21:402021. View Article : Google Scholar
|
|
34
|
Li H, Liang W, Zhang H, Shui Y and Zhang
Z: MicroRNA-4429 restrains colorectal cancer cell invasion and
migration via regulating SMAD3-induced epithelial-mesenchymal
transition. J Cell Physiol. 236:5875–5884. 2021. View Article : Google Scholar
|
|
35
|
Cai P, Wu M, Zhang B, Wu S, Wei H and Wei
L: Long noncoding RNA SNHG12 regulates cell proliferation, invasion
and migration in endometrial cancer by targeting miR4429. Mol Med
Rep. 22:2842–2850. 2020.PubMed/NCBI
|
|
36
|
Pan H, Hong Y, Yu B, Li L and Zhang X:
miR-4429 inhibits tumor progression and epithelial-mesenchymal
transition via targeting CDK6 in clear cell renal cell carcinoma.
Cancer Biother Radiopharm. 34:334–341. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Huang F, Liu M and Zhao Q: UBE2C
mRNA expression controlled by miR-300 and HuR determines its
oncogenic role in gastric cancer. Biochem Biophys Res Commun.
534:597–603. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu J, Wu X, Yang C, Rashid K, Ma C, Hu M,
Ding Q and Jiang H: Anticancer effect of icaritin on prostate
cancer via regulating miR-381-3p and its target gene UBE2C. Cancer
Med. 8:7833–7845. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Y, Tian S, Li X, Ji Y, Wang Z and
Liu C: UBE2C promotes rectal carcinoma via miR-381. Cancer Biol
Ther. 19:230–238. 2018. View Article : Google Scholar : PubMed/NCBI
|
